Neel Singhal

Neel Singhal

Auto-generated profile, based on publicly available information

Neel Singhal

University of California San Francisco, Department of Neurology, California, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2003 in Current Biology
Verified
Journal Article
Closed access
TRTony Ro
Tony Ro
BBBruno Breitmeyer
Bruno Breitmeyer
PBPhilip Burton
Philip Burton
NSNeel S. Singhal
Neel S. Singhal
DLDavid Lane
David Lane

24 August 2015 in Annals of Neurology
Verified
Journal Article
Open access
PDF file
MWMichael Wilson
Michael Wilson
NSNiraj M. Shanbhag
Niraj M. Shanbhag
MRMichael J. Reid
Michael J. Reid
NSNeel S. Singhal
Neel S. Singhal
JGJeffrey M. Gelfand
Jeffrey M. Gelfand
JDJoseph L. DeRisi
Joseph L. DeRisi
Objective: Identification of a particular cause of meningoencephalitis can be challenging owing to the myriad bacteria, viruses, fungi, and parasites that can produce overlapping clinical phenotypes, frequently delaying diagnosis and therapy. Metagenomic deep sequencing (MDS) approaches to infectious disease diagnostics are known for their ability to identify unusual or novel viruses and thus are well suited for investigating possible etiologies of meningoencephalitis.Methods: We present the case of a 74‐year‐old woman with endophthalmitis followed by meningoencephalitis. MDS of her cerebrospinal fluid (CSF) was performed to identify an infectious agent.Results: Sequences aligning to Balamuthia mandrillaris ribosomal RNA genes were identified in the CSF by MDS. Polymerase chain reaction subsequently confirmed the presence of B. mandrillaris in CSF, brain tissue, and vitreous fluid from the patient's infected eye. B. mandrillaris serology and immunohistochemistry for free‐living amoebas on the brain biopsy tissue were positive.Interpretation: The diagnosis was made using MDS after the patient had been hospitalized for several weeks and subjected to costly and invasive testing. MDS is a powerful diagnostic tool with the potential for rapid and unbiased pathogen identification leading to early therapeutic targeting. Ann Neurol 2015;78:Ann Neurol 2015;78:679–696

1 November 2006 in Diabetes
Verified
Journal Article
Open access
PDF file
YQYong Qi
Yong Qi
ZNZhenying Nie
Zhenying Nie
YLYun-Sik Lee
Yun-Sik Lee
NSNeel S. Singhal
Neel S. Singhal
PSPhilipp E. Scherer
Philipp E. Scherer
RARexford S. Ahima
Rexford S. Ahima
Resistin levels are increased in obesity, and hyperresistinemia impairs glucose homeostasis in rodents. Here, we have determined the role of resistin in ob/ob mice that are obese and insulin resistant because of genetic deficiency of leptin. Loss of resistin increased obesity in ob/ob mice by further lowering the metabolic rate without affecting food intake. Nevertheless, resistin deficiency improved glucose tolerance and insulin sensitivity in these severely obese mice, largely by enhancing insulin-mediated glucose disposal in muscle and adipose tissue. In contrast, in C57BL/6J mice with diet-induced obesity but wild-type leptin alleles, resistin deficiency reduced hepatic glucose production and increased peripheral glucose uptake. Resistin deficiency enhanced Akt phosphorylation in muscle and liver and decreased suppressor of cytokine signaling-3 level in muscle, and these changes were reversed by resistin replacement. Together, these results provide strong support for an important role of resistin in insulin resistance and diabetes associated with genetic or diet-induced obesity.

1 December 2006 in Diabetes
Verified
Journal Article
Closed access
PDF file
RARexford S. Ahima
Rexford S. Ahima
YQYong Qi
Yong Qi
NSNeel S. Singhal
Neel S. Singhal
MJMalaka B. Jackson
Malaka B. Jackson
PSPhilipp E. Scherer
Philipp E. Scherer
Adipose tissue secretes factors that control various physiological systems. The fall in leptin during fasting mediates hyperphagia and suppresses thermogenesis, thyroid and reproductive hormones, and immune system. On the other hand, rising leptin levels in the fed state stimulate fatty acid oxidation, decrease appetite, and limit weight gain. These divergent effects of leptin occur through neuronal circuits in the hypothalamus and other brain areas. Leptin also regulates the activities of enzymes involved in lipid metabolism, e.g., AMP-activated protein kinase and stearoyl-CoA desaturase-1, and also interacts with insulin signaling in the brain. Adiponectin enhances fatty acid oxidation and insulin sensitivity, in part by stimulating AMP-activated protein kinase phosphorylation and activity in liver and muscle. Moreover, adiponectin decreases body fat by increasing energy expenditure and lipid catabolism. These effects involve peripheral and possibly central mechanisms. Adipose tissue mediates interconversion of steroid hormones and secretes proinflammatory cytokines, vasoactive peptides, and coagulation and complement proteins. Understanding the actions of these “adipocytokines” will provide insight into the pathogenesis and treatment of obesity and related diseases.

1 July 2014 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
SISarosh R Irani
Sarosh R Irani
JGJeffrey M. Gelfand
Jeffrey M. Gelfand
BBBrianne M. Bettcher
Brianne M. Bettcher
NSNeel S. Singhal
Neel S. Singhal
MGMichael D. Geschwind
Michael D. Geschwind
Importance This observational study describes the efficacy and safety of rituximab in 5 patients with voltage-gated potassium channel (VGKC)–complex/leucine-rich, glioma-inactivated 1 (LGI1) antibody–associated encephalopathy. Rituximab is a monoclonal antibody that targets CD20 and is used to treat other neurologic and nonneurologic diseases. Observations This case series reports sequential seizure frequencies, modified Rankin Scale scores, and VGKC-complex antibody titers in 5 adult patients (median age, 65 years; range, 48-73 years) treated with rituximab. Median time from symptom onset to rituximab initiation was 414 days (range, 312-851 days). One patient showed a rapid clinical improvement after treatment with rituximab alone and experienced a rituximab-responsive clinical relapse. Another showed possible improvement on neuropsychometric memory indexes after rituximab therapy. In contrast, all patients showed robust responses to treatment with glucocorticoids, intravenous immunoglobulins, and/or plasma exchange at some point in their illness. Treatment with glucocorticoids—less so with intravenous immunoglobulins and plasma exchange—was associated with the most marked reductions in VGKC-complex antibodies. The only patient who did not receive glucocorticoids showed the poorest clinical and serologic responses. Conclusions and Relevance Rituximab was well tolerated in this predominantly older adult patient population and may be an effective option for some patients with LGI1 antibody–associated encephalopathy. Glucocorticoid therapy appears particularly efficacious. Earlier rituximab administration and randomized trials are required to formally assess efficacy.

1 September 2008 in American Journal of Physiology-Gastrointestinal and Liver Physiology
Verified
Journal Article
Closed access
PDF file
GVGladys M. Varela
Gladys M. Varela
DADaniel A. Antwi
Daniel A. Antwi
RDRavindra Dhir
Ravindra Dhir
XYXiaoyan Yin
Xiaoyan Yin
NSNeel S. Singhal
Neel S. Singhal
RARexford S. Ahima
Rexford S. Ahima
Diets with high fat content induce steatosis, insulin resistance, and type 2 diabetes. The lipid droplet protein adipose differentiation-related protein (ADRP) mediates hepatic steatosis, but whether this affects insulin action in the liver or peripheral organs in diet-induced obesity is uncertain. We fed C57BL/6J mice a high-fat diet and simultaneously treated them with an antisense oligonucleotide (ASO) against ADRP for 4 wk. Glucose homeostasis was assessed with clamp and tracer techniques. ADRP ASO decreased the levels of triglycerides and diacylglycerol in the liver, but fatty acids, long-chain fatty acyl CoAs, ceramides, and cholesterol were unchanged. Insulin action in the liver was enhanced after ADRP ASO treatment, whereas muscle and adipose tissue were not affected. ADRP ASO increased the phosphorylation of insulin receptor substrate (IRS)1, IRS2, and Akt, and decreased gluconeogenic enzymes and PKCε, consistent with its insulin-sensitizing action. These results demonstrate an important role for ADRP in the pathogenesis of diet-induced insulin resistance.